Terns Pharmaceuticals Inc [NASDAQ: TERN] jumped around 0.06 points on Thursday, while shares priced at $4.32 at the close of the session, up 1.41%.
Terns Pharmaceuticals Inc stock is now -36.93% down from its year-to-date (YTD) trading value. TERN Stock saw the intraday high of $4.35 and lowest of $4.21 per share. The company’s 52-week high price is 11.40, which means current price is +131.64% above from all time high which was touched on 01/06/25.
Compared to the average trading volume of 974.09K shares, TERN reached a trading volume of 263302 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Terns Pharmaceuticals Inc [TERN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TERN shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TERN stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Terns Pharmaceuticals Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on February 28, 2025. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on October 31, 2024, representing the official price target for Terns Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $16, while Mizuho analysts kept a Buy rating on TERN stock.
The Price to Book ratio for the last quarter was 1.16, with the Price to Cash per share for the same quarter was set at 3.83.
How has TERN stock performed recently?
Terns Pharmaceuticals Inc [TERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.00. With this latest performance, TERN shares gained by 23.61% in over the last four-week period, additionally sinking by -21.88% over the last 6 months – not to mention a drop of -22.02% in the past year of trading.
Terns Pharmaceuticals Inc [TERN]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -30.84%, with Return on Assets sitting at -30.84%.
Earnings analysis for Terns Pharmaceuticals Inc [TERN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Terns Pharmaceuticals Inc go to -6.03%.
Insider trade positions for Terns Pharmaceuticals Inc [TERN]
There are presently around $100.24%, or 100.52% of TERN stock, in the hands of institutional investors. The top three institutional holders of TERN stocks are: ORBIMED ADVISORS LLC with ownership of 7.62 million shares, which is approximately 10.2326%. VIVO CAPITAL, LLC, holding 6.18 million shares of the stock with an approximate value of $$42.11 million in TERN stocks shares; and VIVO CAPITAL, LLC, currently with $$41.54 million in TERN stock with ownership which is approximately 8.1923%.
